$SAVA
CASSAVA SCIENCES INC

2020 Q2 Form 10-Q Financial Statement

#000106953020000032 Filed on May 06, 2020

View on sec.gov

Income Statement

Concept 2020 Q2 2020 Q1 2019 Q1
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $820.0K $780.0K $880.0K
YoY Change -3.53% -11.36% -20.0%
% of Gross Profit
Research & Development $574.0K
YoY Change -46.25%
% of Gross Profit
Depreciation & Amortization $0.00 $14.00K $17.00K
YoY Change -17.65% 0.0%
% of Gross Profit
Operating Expenses $1.163M $1.222M $1.451M
YoY Change 0.87% -15.78% -33.04%
Operating Profit -$1.163M -$1.222M -$1.451M
YoY Change 0.87% -15.78% -33.04%
Interest Expense $30.00K $70.00K $90.00K
YoY Change -66.67% -22.22% 800.0%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$1.140M -$1.150M -$1.360M
YoY Change 7.55% -15.44% -37.04%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$1.136M -$1.150M -$1.359M
YoY Change 7.27% -15.38% -37.08%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$46.00K -$46.98K -$79.25K
COMMON SHARES
Basic Shares Outstanding 24.78M 24.73M 17.22M
Diluted Shares Outstanding

Balance Sheet

Concept 2020 Q2 2020 Q1 2019 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $25.30M $25.60M $19.10M
YoY Change 36.76% 34.03% 78.5%
Cash & Equivalents $25.25M $25.60M $19.13M
Short-Term Investments
Other Short-Term Assets $186.0K $277.0K $140.0K
YoY Change 279.59% 97.86% -30.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $25.44M $25.88M $19.27M
YoY Change 36.9% 34.32% 76.74%
LONG-TERM ASSETS
Property, Plant & Equipment $13.00K $33.00K $88.00K
YoY Change -82.67% -62.5% -12.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $12.00K
YoY Change
Total Long-Term Assets $58.00K $100.0K $258.0K
YoY Change -73.87% -61.24% 29.0%
TOTAL ASSETS
Total Short-Term Assets $25.44M $25.88M $19.27M
Total Long-Term Assets $58.00K $100.0K $258.0K
Total Assets $25.50M $25.98M $19.52M
YoY Change 35.59% 33.06% 75.88%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $416.0K $608.0K $495.0K
YoY Change -29.97% 22.83% 23.75%
Accrued Expenses $755.0K $387.0K $243.0K
YoY Change 321.79% 59.26% -19.0%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.314M $1.145M $902.0K
YoY Change 40.23% 26.94% 12.75%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $100.0K
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $100.0K
YoY Change -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.314M $1.145M $902.0K
Total Long-Term Liabilities $0.00 $0.00 $100.0K
Total Liabilities $1.314M $1.145M $970.0K
YoY Change 33.81% 18.04% 21.25%
SHAREHOLDERS EQUITY
Retained Earnings -$170.9M -$169.7M -$165.3M
YoY Change 2.7% 2.67%
Common Stock $25.00K $25.00K $17.00K
YoY Change 47.06% 47.06%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $24.18M $24.83M $18.55M
YoY Change
Total Liabilities & Shareholders Equity $25.50M $25.98M $19.52M
YoY Change 35.59% 33.06% 75.88%

Cashflow Statement

Concept 2020 Q2 2020 Q1 2019 Q1
OPERATING ACTIVITIES
Net Income -$1.136M -$1.150M -$1.359M
YoY Change 7.27% -15.38% -37.08%
Depreciation, Depletion And Amortization $0.00 $14.00K $17.00K
YoY Change -17.65% 0.0%
Cash From Operating Activities -$800.0K -$1.194M -$604.0K
YoY Change 33.33% 97.68% -63.24%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00 $18.00K
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities $300.0K $100.0K
YoY Change
Cash From Investing Activities $300.0K $100.0K -$18.00K
YoY Change -655.56%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 200.0K 3.613M -60.00K
YoY Change -6121.67% -103.16%
NET CHANGE
Cash From Operating Activities -800.0K -1.194M -604.0K
Cash From Investing Activities 300.0K 100.0K -18.00K
Cash From Financing Activities 200.0K 3.613M -60.00K
Net Change In Cash -300.0K 2.519M -682.0K
YoY Change -50.0% -469.35% -367.45%
FREE CASH FLOW
Cash From Operating Activities -$800.0K -$1.194M -$604.0K
Capital Expenditures $0.00 $0.00 $18.00K
Free Cash Flow -$800.0K -$1.194M -$622.0K
YoY Change 33.33% 91.96%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
TX
CY2020Q1 dei Amendment Flag
AmendmentFlag
false
CY2020Q1 dei City Area Code
CityAreaCode
512
CY2020Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2020Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2020Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
CY2020Q1 dei Document Period End Date
DocumentPeriodEndDate
2020-03-31
CY2020Q1 dei Document Type
DocumentType
10-Q
CY2020Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
7801 N. Capital of Texas Highway
CY2020Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 260
CY2020Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Austin
CY2020Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
78731
CY2020Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001069530
CY2020Q1 dei Entity Registrant Name
EntityRegistrantName
CASSAVA SCIENCES INC
CY2020Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2020Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2020Q1 dei Entity File Number
EntityFileNumber
000-29959
CY2020Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2020Q1 dei Entity Incorporation State Country Name
EntityIncorporationStateCountryName
Delaware
CY2020Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
24779902
CY2020Q1 dei Entity Shell Company
EntityShellCompany
false
CY2020Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
911911336
CY2020Q1 dei Local Phone Number
LocalPhoneNumber
501-2444
CY2019Q1 sava Common Stock Net Income Loss Shares
CommonStockNetIncomeLossShares
CY2020Q1 sava Common Stock Net Income Loss Shares
CommonStockNetIncomeLossShares
CY2020Q1 sava Common Stock Warrant Shares Exercise
CommonStockWarrantSharesExercise
2888092
CY2019Q1 sava Operating Lease Liability Non Current Reduction And Offsetting Reduction Right Of Use Assets
OperatingLeaseLiabilityNonCurrentReductionAndOffsettingReductionRightOfUseAssets
22500000
CY2020Q1 sava Operating Lease Liability Non Current Reduction And Offsetting Reduction Right Of Use Assets
OperatingLeaseLiabilityNonCurrentReductionAndOffsettingReductionRightOfUseAssets
22500000
CY2020Q1 sava Operating Leases Future Minimum Payments Imputed Interest
OperatingLeasesFutureMinimumPaymentsImputedInterest
8000
CY2020Q1 sava Operating Leases Future Minimum Payments Remainder Of Fiscal Year And Due In Two Years Total
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYearAndDueInTwoYearsTotal
75000
CY2019Q1 sava Reduction To Research And Development Expense
ReductionToResearchAndDevelopmentExpense
800000
CY2020Q1 sava Reduction To Research And Development Expense
ReductionToResearchAndDevelopmentExpense
1300000
CY2019Q1 sava Research And Development Expense Net Of Grant Reimbursement
ResearchAndDevelopmentExpenseNetOfGrantReimbursement
574000
CY2020Q1 sava Research And Development Expense Net Of Grant Reimbursement
ResearchAndDevelopmentExpenseNetOfGrantReimbursement
544000
CY2020Q1 us-gaap Assets
Assets
25977000
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
22000
CY2020Q1 us-gaap Common Stock Value
CommonStockValue
25000
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
17219300
CY2019Q1 sava Shares Issued Costs From Sale2018 Sale Of Common Stock And Warrants
SharesIssuedCostsFromSale2018SaleOfCommonStockAndWarrants
CY2019Q1 sava Stockholders Equity Issuance Of Common Stock And Warrants Net Of Issuance Costs
StockholdersEquityIssuanceOfCommonStockAndWarrantsNetOfIssuanceCosts
60000
CY2020Q1 sava Stockholders Equity Warrant Shares Exercise
StockholdersEquityWarrantSharesExercise
3613000
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
453000
CY2020Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
608000
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
777000
CY2020Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
387000
CY2019Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
190664000
CY2020Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
194544000
CY2019Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
344000
CY2020Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
270000
CY2019Q4 us-gaap Assets
Assets
23486000
CY2019Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
17219300
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
21841810
CY2020Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
24729902
CY2019Q4 us-gaap Assets Current
AssetsCurrent
23349000
CY2020Q1 us-gaap Assets Current
AssetsCurrent
25877000
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
19807000
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
23081000
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
2519000
CY2019Q4 us-gaap Certificates Of Deposit At Carrying Value
CertificatesOfDepositAtCarryingValue
13000000
CY2020Q1 us-gaap Certificates Of Deposit At Carrying Value
CertificatesOfDepositAtCarryingValue
20000000
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000
CY2020Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
21841810
CY2020Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
24729902
CY2020Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2019Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.08
CY2019Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
17000
CY2020Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
14000
CY2020Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.05
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
58000
CY2020Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
72000
CY2020Q1 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
100000
CY2019Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
877000
CY2020Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
778000
CY2019Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2019Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
201000
CY2020Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
155000
CY2019Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
87000
CY2020Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-390000
CY2019Q1 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
1000
CY2020Q1 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
14000
CY2019Q1 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-93000
CY2020Q1 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
9000
CY2019Q1 us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
12000
CY2020Q1 us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
2000
CY2019Q1 us-gaap Interest And Other Income
InterestAndOtherIncome
92000
CY2020Q1 us-gaap Interest And Other Income
InterestAndOtherIncome
72000
CY2020Q1 us-gaap Lessee Operating Lease Discount Rate
LesseeOperatingLeaseDiscountRate
0.0550
CY2019Q4 us-gaap Liabilities
Liabilities
1387000
CY2020Q1 us-gaap Liabilities
Liabilities
1145000
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
23486000
CY2020Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
25977000
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1387000
CY2020Q1 us-gaap Liabilities Current
LiabilitiesCurrent
1145000
CY2020Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3613000
CY2020Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
100000
CY2019Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-604000
CY2020Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1194000
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-1359000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-1150000
CY2019Q1 us-gaap Operating Expenses
OperatingExpenses
1451000
CY2020Q1 us-gaap Operating Expenses
OperatingExpenses
1222000
CY2019Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-1451000
CY2020Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-1222000
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
90000
CY2020Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
67000
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
90000
CY2020Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
67000
CY2020Q1 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
67000
CY2020Q1 us-gaap Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
75000
CY2019Q4 us-gaap Other Assets Current
OtherAssetsCurrent
268000
CY2020Q1 us-gaap Other Assets Current
OtherAssetsCurrent
277000
CY2019Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
9000
CY2020Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
11000
CY2019Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
18000
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2020Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2020Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2020Q1 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
100000
CY2020Q1 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
3613000
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
47000
CY2020Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
33000
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-168587000
CY2020Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-169737000
CY2019Q1 us-gaap Share Based Compensation
ShareBasedCompensation
344000
CY2020Q1 us-gaap Share Based Compensation
ShareBasedCompensation
270000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
22099000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
24832000
CY2018Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
19628000
CY2019Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
22099000
CY2020Q1 us-gaap Use Of Estimates
UseOfEstimates
<div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-weight:bold;font-style:italic;">Use of Estimates</font><font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-family:Tahoma;font-style:italic;">&#xFEFF;</font><font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;">The Company makes estimates and assumptions in preparing its financial statements in conformity with GAAP. These estimates and assumptions affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenue earned and expenses incurred during the reporting period. The Company evaluates&nbsp;its estimates on an ongoing basis, including those estimates related to agreements, research collaborations and investments. Actual results could differ from these estimates</font><font style="display: inline;color:#000000;"> and assumptions.</font><font style="display: inline;">&nbsp;</font> </p> <p><font size="1"> </font></p> </div> </div>
CY2019Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
17162000
CY2020Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
24481000

Files In Submission

Name View Source Status
0001069530-20-000032-index-headers.html Edgar Link pending
0001069530-20-000032-index.html Edgar Link pending
0001069530-20-000032.txt Edgar Link pending
0001069530-20-000032-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
sava-20200331.xml Edgar Link completed
sava-20200331.xsd Edgar Link pending
sava-20200331x10q.htm Edgar Link pending
sava-20200331xex31_1.htm Edgar Link pending
sava-20200331xex31_2.htm Edgar Link pending
sava-20200331xex32_1.htm Edgar Link pending
sava-20200331_cal.xml Edgar Link unprocessable
sava-20200331_def.xml Edgar Link unprocessable
sava-20200331_lab.xml Edgar Link unprocessable
sava-20200331_pre.xml Edgar Link unprocessable
Show.js Edgar Link pending